Various studies over the years have linked prenatal use of the pain reliever paracetamol (acetaminophen) with neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD) in children, but many of the studies were small, poorly designed, or found only weak associations. A recent “umbrella” review in Developmental Medicine & Child Neurology reveals that the available scientific evidence does not support a causal relationship between paracetamol and neurodevelopmental disorders.
For the review, 7 meta-analyses were included, encompassing more than 3 million participants. Unrestricted assessments showed small positive associations between prenatal paracetamol exposure and both autism and ADHD, but after restricting assessments to higher-quality meta-analyses and studies, effect estimates were substantially attenuated and approached null. No robust epidemiological evidence supported a causal association.
“A widely debated question deserves more than headlines—it deserves robust evidence. Our findings show that the apparent association between prenatal paracetamol exposure and autism or ADHD weakens as methodological quality improves, challenging the interpretation of a causal link and supporting evidence-based decisions during pregnancy,” said first author Hoda Tayebi Hillali, DDS, MSc, of the University of Santiago de Compostela, in Spain.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70512
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Developmental Medicine & Child Neurology is a multidisciplinary journal that has defined the fields of paediatric neurology and childhood-onset neurodisability for over 60 years. DMCN disseminates the latest clinical research results globally to enhance the care and improve the lives of disabled children and their families.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.